{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:26:03Z","timestamp":1770492363140,"version":"3.49.0"},"reference-count":67,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grosserer L. F. Foghts Fond, Charlottenlund, Denmark","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,7,20]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Type 2 diabetes (T2D) is characterised by elevated plasma glucose, free fatty acid (FFA) and insulin concentrations, and this metabolic profile is linked to diabetic cardiomyopathy, a diastolic dysfunction at first and increased cardiovascular disease (CVD) risk. Shifting cardiac metabolism towards glucose utilisation has been suggested to improve cardiovascular function and CVD risk, but insulin treatment increases overall glucose oxidation and lowers lipid oxidation, without reducing CVD risk, whereas SGLT2 inhibitors (SGLT2i) increase FFA, ketone body concentrations and lipid oxidation, while decreasing insulin concentrations and CVD risk. The aim of the present study is to elucidate the importance of different metabolic profiles obtained during treatment with a SGLT2i versus insulin for myocardial function in patients with T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analyses<\/jats:title>\n                  <jats:p>Randomised, crossover study, where 20 patients with T2D and body mass index&gt;28 kg\/m<jats:sup>2<\/jats:sup> receive 25 mg empagliflozin daily or NPH insulin two times per day first for 5 weeks followed by a 3-week washout before crossing over to the remaining treatment. Insulin treatment is titrated to achieve similar glycaemic control as with empagliflozin. In those randomised to insulin first, glycaemia during an initial empagliflozin run-in period prior to randomisation serves as target glucose. Metabolic and cardiac evaluation is performed before and at the end of each treatment period.<\/jats:p>\n                  <jats:p>The primary endpoint is change (treatment\u2014washout) in left ventricular peak filling rate, as assessed by cardiac MRI with and without acute lowering of plasma FFAs with acipimox. Secondary and explorative endpoints are changes in left atrial passive emptying fraction, left ventricular ejection fraction, central blood volume and metabolic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study is approved by the Danish Medicines Agency (ref. nr.: 2017061587), the Danish Data Protection Agency (ref. nr.: AHH-2017-093) and the Capital Region Ethics Committee (ref. nr.: H-17018846). The trial will be conducted in accordance with ICH-GCP guidelines and the Declaration of Helsinki and all participants will provide oral and written informed consent. Our results, regardless of outcome, will be published in relevant scientific journals and we also will seek to disseminate results through presentations at scientific meetings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>EudraCT: 2017-002101.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054100","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T12:01:20Z","timestamp":1660219280000},"page":"e054100","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8386-4864","authenticated-orcid":false,"given":"Roopameera","family":"Thirumathyam","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Arne","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Exercise and Sports, Section of Molecular Physiology, Faculty of Science, University of Copenhagen, Kobenhavn, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Peter","family":"Goetze","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mogens","family":"Fenger","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Hvidovre Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Van Hall","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Kobenhavn, Denmark"},{"name":"Clinical Metabolomics Core Facility, Clinical Biochemistry, Rigshospitalet, Kobenhavn, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Dixen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre University Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Kobenhavn, Denmark"},{"name":"NovoNordisk Center for Basic Metabolic Research, University of Copenhagen, Kobenhavn, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Vejlstrup","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per Lav","family":"Madsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev Hospital, Herlev, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5764-6377","authenticated-orcid":false,"given":"Nils Bruun","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"2025101811173405000_12.8.e054100.1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"2025101811173405000_12.8.e054100.2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051249"},{"key":"2025101811173405000_12.8.e054100.3","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1097"},{"key":"2025101811173405000_12.8.e054100.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.8.1160"},{"key":"2025101811173405000_12.8.e054100.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-6-200409210-00007"},{"key":"2025101811173405000_12.8.e054100.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.194"},{"key":"2025101811173405000_12.8.e054100.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.12.026"},{"key":"2025101811173405000_12.8.e054100.8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ehjci\/jey164","article-title":"Predictive value of echocardiography in type 2 diabetes","volume":"20","author":"J\u00f8rgensen","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025101811173405000_12.8.e054100.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-010-0180-x"},{"key":"2025101811173405000_12.8.e054100.10","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2878-x","article-title":"Cardiovascular magnetic resonance evaluation of left ventricular peak filling rate using steady-state free precession and phase contrast sequences","volume":"5","author":"Komi","year":"2016","journal-title":"Springerplus"},{"key":"2025101811173405000_12.8.e054100.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00625-9"},{"key":"2025101811173405000_12.8.e054100.12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.17987\/icfj.v17i0.597","article-title":"Modulation of cardiac metabolism in heart failure","volume":"17","author":"Rosano","year":"2019","journal-title":"ICFJ"},{"key":"2025101811173405000_12.8.e054100.13","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(55)90218-7"},{"key":"2025101811173405000_12.8.e054100.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.074"},{"key":"2025101811173405000_12.8.e054100.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(96)00245-3"},{"key":"2025101811173405000_12.8.e054100.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.4.437"},{"key":"2025101811173405000_12.8.e054100.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi199"},{"key":"2025101811173405000_12.8.e054100.18","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00126-K"},{"key":"2025101811173405000_12.8.e054100.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810625"},{"key":"2025101811173405000_12.8.e054100.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6898"},{"key":"2025101811173405000_12.8.e054100.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431"},{"key":"2025101811173405000_12.8.e054100.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"2025101811173405000_12.8.e054100.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"2025101811173405000_12.8.e054100.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"2025101811173405000_12.8.e054100.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025101811173405000_12.8.e054100.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2025101811173405000_12.8.e054100.27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018245","article-title":"Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes","volume":"98","author":"Zou","year":"2019","journal-title":"Medicine"},{"key":"2025101811173405000_12.8.e054100.28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"2025101811173405000_12.8.e054100.29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"2025101811173405000_12.8.e054100.30","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2724"},{"key":"2025101811173405000_12.8.e054100.31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12572"},{"key":"2025101811173405000_12.8.e054100.32","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na+ \/H+ exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025101811173405000_12.8.e054100.33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"2025101811173405000_12.8.e054100.34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"2025101811173405000_12.8.e054100.35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"2025101811173405000_12.8.e054100.36","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0921"},{"key":"2025101811173405000_12.8.e054100.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2016.02.015","article-title":"EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives","volume":"30","author":"J\u00f8rgensen","year":"2016","journal-title":"J Diabetes Complications"},{"key":"2025101811173405000_12.8.e054100.38","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-020-01359-z","article-title":"Sodium-Glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: the good and the bad","volume":"20","author":"Ekanayake","year":"2020","journal-title":"Curr Diab Rep"},{"key":"2025101811173405000_12.8.e054100.39","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"2025101811173405000_12.8.e054100.40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.036459"},{"key":"2025101811173405000_12.8.e054100.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)32537-9"},{"key":"2025101811173405000_12.8.e054100.42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.numecd.2016.03.012","article-title":"Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes","volume":"26","author":"Wolf","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025101811173405000_12.8.e054100.43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.645184"},{"key":"2025101811173405000_12.8.e054100.44","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-234914"},{"key":"2025101811173405000_12.8.e054100.45","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-208991"},{"key":"2025101811173405000_12.8.e054100.46","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-102"},{"key":"2025101811173405000_12.8.e054100.47","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"Sglt2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"2025101811173405000_12.8.e054100.48","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00365.2012"},{"key":"2025101811173405000_12.8.e054100.49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801083"},{"key":"2025101811173405000_12.8.e054100.50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.3.717"},{"key":"2025101811173405000_12.8.e054100.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02381-0"},{"key":"2025101811173405000_12.8.e054100.52","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jes103"},{"key":"2025101811173405000_12.8.e054100.53","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00365.2012"},{"key":"2025101811173405000_12.8.e054100.54","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1580"},{"key":"2025101811173405000_12.8.e054100.55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2213-8587(15)00384-8","article-title":"Getting to the heart of the matter in type 2 diabetes","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025101811173405000_12.8.e054100.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.10.013"},{"key":"2025101811173405000_12.8.e054100.57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2020.08.015","article-title":"Disruption of energy utilization in diabetic cardiomyopathy; a mini review","volume":"54","author":"Nirengi","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"2025101811173405000_12.8.e054100.58","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028"},{"key":"2025101811173405000_12.8.e054100.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00047-3"},{"key":"2025101811173405000_12.8.e054100.60","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0655"},{"key":"2025101811173405000_12.8.e054100.61","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0694"},{"key":"2025101811173405000_12.8.e054100.62","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00854.2012"},{"key":"2025101811173405000_12.8.e054100.63","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01175-5","article-title":"Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study","volume":"20","author":"Rau","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025101811173405000_12.8.e054100.64","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/dom.14363","article-title":"Effects of 6\u2009weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study","volume":"23","author":"Oldgren","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025101811173405000_12.8.e054100.65","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the asset study","volume":"20","author":"Hiruma","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025101811173405000_12.8.e054100.66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13135","article-title":"A review of dipeptidyl peptidase-4 inhibitors. hot topics from randomized controlled trials","volume":"20 Suppl 1","author":"Deacon","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025101811173405000_12.8.e054100.67","unstructured":"Nordsborg N , Timmerman M . Testmanual - patientinterview og konditionstest. 2.0. K\u00f8benhavn. Sundhedsstyrelsen, 2006."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:17:47Z","timestamp":1760811467000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,11]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bmjopen-2021-054100"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054100","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}